- Market Capitalization, $K 57,359
- Shares Outstanding, K 40,394
- Annual Sales, $ 0 K
- Annual Income, $ -56,620 K
- 60-Month Beta -0.04
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 0.46
|Period||Period Low||Period High||Performance|
| || |
-0.7900 (-35.75%)since 10/25/22
| || |
-2.0600 (-59.20%)since 08/25/22
| || |
-7.1700 (-83.47%)since 11/24/21
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.
Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was...
The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually...
|3rd Resistance Point||1.7728|
|2nd Resistance Point||1.6914|
|1st Resistance Point||1.5557|
|1st Support Level||1.3386|
|2nd Support Level||1.2572|
|3rd Support Level||1.1215|